STOCK TITAN

Olema Pharmaceuticals, Inc. - OLMA STOCK NEWS

Welcome to our dedicated page for Olema Pharmaceuticals news (Ticker: OLMA), a resource for investors and traders seeking the latest updates and insights on Olema Pharmaceuticals stock.

Olema Pharmaceuticals, Inc. (OLMA) is a clinical-stage biopharmaceutical company advancing targeted therapies for endocrine-driven breast cancers. This page provides investors and healthcare professionals with timely updates on clinical developments, financial disclosures, and strategic initiatives.

Access consolidated information about OLMA's lead candidate palazestrant (OP-1250), an oral complete estrogen receptor antagonist/SERD, and other pipeline assets like the KAT6 inhibitor OP-3136. Track regulatory milestones, partnership announcements, and peer-reviewed research findings in one centralized location.

Key updates include clinical trial progress, scientific conference presentations, and financial results. All content is sourced from official company communications and verified industry reports to ensure accuracy.

Bookmark this page for streamlined access to OLMA's latest developments in women's oncology therapeutics. Check regularly for essential updates impacting treatment innovation and corporate strategy.

Rhea-AI Summary
Olema Pharmaceuticals appoints Scott Garland to its Board of Directors
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.13%
Tags
management
-
Rhea-AI Summary
Olema Pharmaceuticals presents preclinical data on novel compounds targeting KAT6 at cancer conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.89%
Tags
none
-
Rhea-AI Summary
Olema Pharmaceuticals announces amendment to clinical collaboration and supply agreement with Novartis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.54%
Tags
none
Rhea-AI Summary
Olema Pharmaceuticals granted stock options to one new employee, allowing them to purchase 30,000 shares of common stock. The options vest over four years and have a 10-year term with an exercise price of $11.66 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.78%
Tags
none
-
Rhea-AI Summary
Olema Pharmaceuticals announces poster presentation on new discovery compounds targeting KAT6 at ANE 2023 conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.35%
Tags
none
-
Rhea-AI Summary
Olema Pharmaceuticals, Inc. to present at upcoming investor conferences in September.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.8%
Tags
conferences
Rhea-AI Summary
Olema Pharmaceuticals grants stock options to new employee
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.02%
Tags
none
-
Rhea-AI Summary
Olema Pharmaceuticals announces $130 million equity private placement and $50 million credit facility. Proceeds will fund research and development and support clinical trials. Financing provides sufficient capital into 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.51%
Tags
none
-
Rhea-AI Summary
Olema Pharmaceuticals initiates Phase 3 trial, presents new data for palazestrant. Cash balance of $167.4M expected to fund operations into Q2 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.05%
Tags
Rhea-AI Summary
Olema Pharmaceuticals, a clinical-stage biopharmaceutical company, has granted stock options to two new employees. The options allow them to purchase a total of 29,100 shares of the company's common stock. The options vest over four years, with 25% vesting on the first anniversary and the rest vesting in equal monthly installments over the following three years. The options have a 10-year term and an exercise price of $9.08 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.73%
Tags
none
Olema Pharmaceuticals, Inc.

Nasdaq:OLMA

OLMA Rankings

OLMA Stock Data

302.03M
65.55M
3.21%
101.58%
11.4%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN FRANCISCO